Assertio Holdings (ASRT) was materially affected by its flagship drug going generic, but the pharma firm still stands to make a major comeback. duckycards/E+ via Getty Images Assertio Holdings, Inc. (NASDAQ:ASRT) shares took a heavy beating in 2023 when the pharma firm's flagship drug went generic. Thus far in 2024, ASRT stock has stabilized, but price action remains choppy. At first glance, this suggests waning confidence in the "comeback story" surrounding the company. Taking a closer look, there's more t ...